Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Platform for Analyzing Targetable Tumor Mutations Network (Main-study)

NCT05489250 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT05489250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05489250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Platform for Analyzing Targetable Tumor Mutations Network (Main-study)
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Observational
Overall status
Terminated
Start date
October 28, 2020
Completion date
June 30, 2025
Enrollment
565 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, gallbladder cancer, hepatocellular cancer, oesophageal cancer, pancreatic cancer, stomach cancer